Conduent (CNDT) Q3 2026 Earnings Call Transcript

Conduent reported Q3 continuing-operations revenue of $534 million, down 11.7% year over year, while adjusted EBITDA rose 16.1% to $36 million and margin expanded 160 basis points to 6.7%. Adjusted free cash flow was negative $117 million, which management said was significantly affected by a temporary pause in receivables factoring; full-year 2026 guidance was reaffirmed at $2.15 billion–$2.25 billion in revenue and $140 million–$170 million in adjusted EBITDA. The company completed its $164 million public transit sale and refinanced its credit facilities to $447 million of commitments, with maturities extended to May 2029; management cited a $2.9 billion qualified pipeline but said converting it into revenue remains a key challenge.

Analysis

CNDT’s key inflection is whether cost reduction can outrun revenue attrition—not whether adjusted margin improves for another quarter. With the largest commercial account now exited, that specific drag should ease, but the business still needs new wins to replace churn; a large qualified pipeline is not equivalent to booked, implemented, recurring revenue. Government implementations can create a timing mismatch: percentage-of-completion revenue may arrive before steady-state operations, while award delays defer both conversion and cash. Watch recurring run-rate revenue and implementation cash collection, not headline pipeline or total contract value.

The margin improvement is encouraging but fragile: further cuts can support near-term EBITDA while reducing delivery capacity or implementation quality, risking renewals and future growth. The cash-flow explanation is also a verification point, not yet proof of normalized cash generation; factoring resumption, working-capital trends, and post-divestiture liquidity need confirmation. Refinancing buys execution time but does not remove the leverage risk if revenue continues falling.

Near term, results broadly in line with guidance may limit catalyst-driven upside. Over 1–3 months, monitor government award timing and whether new ACV translates into revenue. Over 6–18 months, the thesis hinges on stabilizing commercial churn, successful Medicaid implementations, and cost savings without service degradation. The contrarian risk is that investors capitalize margin expansion and divestiture proceeds before recurring growth is demonstrated. Humana is named as an existing relationship, but the disclosed expansion is not enough to infer material earnings sensitivity for HUM.

Key Decisions for Investors

• Keep CNDT as a high-risk watch/underweight rather than buying the pipeline narrative; do not add until reported revenue stabilizes and new-business conversion is visible in recurring revenue.
• For an existing CNDT position, use the next results as a de-risking checkpoint: verify factoring is operating normally, adjusted free cash flow improves, and net leverage falls from the temporarily elevated level. Reassess if cash flow remains materially negative after the stated temporary disruption passes.
• Catalyst watch for the next 1–3 months: government awards and implementation milestones. Seek evidence that awarded work is producing billable revenue and cash, rather than relying on proposal counts or pipeline size.
• Falsification of the cautious thesis would be sequential revenue stabilization alongside sustained margin gains and positive normalized free cash flow; worsening commercial churn, delayed awards, or savings shortfalls would strengthen it. No HUM trade is supported by the limited customer disclosure.